Quantcast

Latest BioMarin Pharmaceutical Stories

2014-09-10 08:31:32

Editor Note: For more information about this release, please scroll to bottom. LONDON, September 10, 2014 /PRNewswire/ -- On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32,...

2014-08-18 12:26:52

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular...

2014-07-30 16:29:22

TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited...

2014-07-07 08:27:54

Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder TORONTO, July 7, 2014 /CNW/ - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Health Canada has approved VIMIZIM(TM)(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome. The approval makes VIMIZIM the first and only pharmaceutical...

2014-06-23 16:25:27

HAYWARD, Calif., June 23, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Brian R. Mueller currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical...

2014-06-23 08:29:48

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Tobira Therapeutics, a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today the appointment of four directors to its Board: Jeffrey H. Cooper, Craig S. Gibbs, Ph.D., Gwen A. Melincoff and Graeme J. Moyle, M.B.B.S., M.D. "I am very pleased to add to our Board of Directors a group of diverse and talented individuals who bring a wealth of experience and unique skill set...

2014-05-30 08:23:32

Editor Note: For more information about this release, please scroll to bottom. On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, with the index advancing 2.45%...

2014-05-12 08:31:48

REDWOOD CITY, Calif., May 12, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D. as Senior Vice President, Global Regulatory Affairs. Dr. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies. "Lisa brings a strong strategic, scientific and global mindset to the regulatory strategy for our...

2014-03-31 23:37:07

Top Tier Panelists from Onyx Pharmaceuticals, BioMarin Pharmaceutical, San Francisco State University, and Clinovo Share Experience on How to Conduct Successful Outsourcing Strategies Sunnyvale, CA (PRWEB) March 31, 2014 Outsourcing experts from Onyx Pharmaceuticals, San Francisco State University (SFSU), BioMarin Pharmaceutical, and Clinovo discussed the topic 'Manage In-house and Outsourced Clinical Trials: Vendor Selection, Project Coordination, and Resource Management' at the...

2014-03-26 12:29:27

Editor Note: For more information about this release, please scroll to bottom. LONDON, March 26, 2014 /PRNewswire/ -- On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related